Novavax Gets Competitive Shot As Third ’23-’24 COVID-19 Vaccine Provider In US
Executive Summary
After long lagging behind Pfizer/BioNTech and Moderna, authorization of its XBB.1.5 variant-based vaccine may give Novavax a boost as an mRNA alternative could be more appealing to some. But unlike its competitors it does not have a pediatric indication.